Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor
prognosis. For almost two decades, the world standard treatment regimen for unresectable …

Extract Knowledge from clinical trials of pleural diseases has revolutionised clinical practice
in recent decades. These exciting advances have made pleural medicine a rapidly …

Pleural mesothelioma is an aggressive and incurable cancer1 with a rising global incidence,
2 especially in low-income countries. Pleural mesothelioma is always fatal, despite attempts …

Simple Summary Advances in malignant pleural mesothelioma research have led to the
approval of first-line immunotherapies and the development of numerous trials of new first …

Purpose The mesothelin-targeting antibody-drug conjugate anetumab ravtansine was
evaluated in combination with the programmed cell death-1 (PD-1) inhibitor pembrolizumab …

Pleural mesothelioma is a very aggressive malignancy that arises from the pleural
mesothelial cell lining and is linked strongly to prior asbestos exposure. The ban on …

Purpose Malignant pleural mesothelioma (MPM) is an aggressive cancer with long latency
and poor prognosis. The real-world treatment patterns and humanistic burden of MPM in an …

In recent years, the treatment paradigm for pleural mesothelioma (PM) has been expanded
after the development and rollout of immune checkpoint inhibitors (ICIs), 1 whereas the …

曙光破晓,晨曦初现——恶性胸膜间皮瘤诊治展望 Page 1 循证医学2023年第23卷第5期The
Journal of Evidence⁃Based Medicine,2023,Vol.23,No.5 [关键词] 恶性胸膜间皮瘤;诊断;治疗 [中 …

Immune checkpoint inhibitors have opened up new possibilities in clinical oncology.
Monoclonal antibodies have shown their high clinical efficiency. They block CTLA-4, PD-1 …